Comparison of the drug approval processes in the US, the EU and Canada

Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing

Volumn 1, Issue 3, 2001, Pages 224-235

  Paul, David ^a  

^a NONE

Author keywords

approval processes; drug; international comparison; pharmaceutical

Indexed keywords

EID: 84990341429     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1057/palgrave.jmm.5040032     Document Type: Article

References (46)

1. Andersson F. (1992) ‘The international diffusion of new drugs: A comparative study of seven industrialized countries’, Journal of Research in Pharmaceutical Economics, 4(2) pp. 43–62.
2. Kessler D. A. Hass A. E. Frieden K. L. Lumpkin M. Temple R. (1996) ‘Approval of new drugs in the United States: Comparison with the United Kingdom, Germany, and Japan’, Journal of the American Medical Association, 276(22) pp. 1826–1831.
3. Rawson N. S. B. (1995) ‘The timeliness of new drug approvals in Canada,’ International Journal of Health Services, 25(1) pp. 153–165.
4. Peterson E. A. (1992) ‘A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States’, Journal of Clinical Pharmacology, 32 pp. 889–896.
5. Rawson N. S. B. Kaitin K. I. Thomas K. E. Perry G. (1998) ‘Drug review in Canada: A comparison with Australia, Sweden, the United Kingdom, and the United States’, Drug Information Journal, 32 pp. 1133–1141.
6. Rawson N. S. B. (2000) ‘Time required for approval of new drugs in Canada, Australia, Sweden, the UK, and the USA in 1996–1998’, Canadian Medical Association Journal, 162(4) pp. 501–504.
7. Bodenheimer T. (2000) ‘Uneasy alliance: Clinical investigators and the pharmaceutical industry’, New England Journal of Medicine, 342(20) pp. 1539–1544.
8. Merrill R. A. (1994) ‘Regulation of drugs and devices: An evolution’, Health Affairs, 13(3) pp. 47–69.
9. Harris G. (2000) ‘Drug firms, stymied in the lab, become marketing machines’, Wall Street Journal, July 6, A1, A12.
10. Lin J. H. Lu A. Y. (1997) ‘The role of pharmacokenetics and metabolism in drug discovery and development’, Pharmacologichol Review, 49 pp. 403–449.
11. www.fda.gov/fdac/special/newdrug/begin.html [accessed March 1999].
12. Mattieu M. (1995) Developments in International Pharmaceutical Regulation: Implications for the United States, Lexington, MA: Eastern Research Group, Inc.
13. Mattieu M. (1995) Developments in International Pharmaceutical Regulation: Implications for the United States, Lexington, MA: Eastern Research Group, Inc.
14. www.fda.gov/fdac/special/newdrug/guinea.html [accessed March 1999].
15. www.fda.gov/fdac/special/newdrug/guinea.html [accessed March 1999].
16. Stringer S. (1996) ‘An overview of how the food and drug administration regulates new drug development in the United States’, Drug Information Journal, 30(3) pp. 745–751.
17. Searle Sales Training Notes (October 1997).
18. www.fda.gov/fdac/special/newdrug/advise.html [accessed March 1999].
19. www.fda.gov/fdac/special/newdrug/benefits.html [accessed March 1999].
20. www.fda.gov/fdac/special/newdrug/benefits.html [accessed March 1999].
21. www.fda.gov/cder/handbook/postmark.htm (1997 Center for Drug Evaluation and Research Handbook) [accessed March 1999].
22. Kessler D. A. Hass A. E. Frieden K. L. Lumpkin M. Temple R. (1996) Center for Drug Evaluation and Research Handbook)
23. Hart C. (1999) ‘Drug approvals: Safe at any speed?’, Modern Drug Discovery, 2(5) pp. 25–26, 28.
24. Kaitin K. I. (1997) ‘The Prescription Drug User Fee Act of 1992 and the new drug development process’, American Journal of Therapeutics, 4 pp. 167–172.
25. Shi L. Singh D. A. (2001) Developments in International Pharmaceutical Regulation: Implications for the United States, Lexington, MA: Eastern Research Group, Inc.
26. Drews J. (1998) Developments in International Pharmaceutical Regulation: Implications for the United States, Lexington, MA: Eastern Research Group, Inc.
27. Kessler D. A. Frieden K. L. (1995) ‘Faster evaluation of vital drugs’, Scientific American, March pp. 48–54.
28. DiMasi J. A. Manocchia M. (1997) ‘Initiatives to speed new drug development and regulatory review: The impact of FDA-sponsored conferences’, Drug Information Journal, 31(2) pp. 771–788.
29. Eastern Research Group, Inc. (1995) Developments in International Pharmaceutical Regulation: Implications for the United States, Lexington, MA: Eastern Research Group, Inc.
30. Evers P. T. (1995) Developments in International Pharmaceutical Regulation: Implications for the United States, Lexington, MA: Eastern Research Group, Inc.
31. Evers P. T. (1995) Developments in International Pharmaceutical Regulation: Implications for the United States, Lexington, MA: Eastern Research Group, Inc.
32. Sauer F. (1997) ‘A new and fast drug approval system in Europe’, Drug Information Journal, 31 pp. 1–6.
33. Healey E. M. Kaitin K. I. (1999) ‘The European Agency for the Evaluation of Medicinal Products' centralized procedure for product approval: Current status’, Drug Information Journal, 33(4) pp. 969–978.
34. www.eudra.org/emea.html; Fees Payable [accessed March 1999].
35. Evers P. T. (1995) Drug Information Journal
36. Currie W. J. C. Löfgren M. (1996) Developments in International Pharmaceutical Regulation: Implications for the United States, Lexington, MA: Eastern Research Group, Inc.
37. Evers P. T. (1995) Developments in International Pharmaceutical Regulation: Implications for the United States p. 34.
38. Evers P. T. (1995) Developments in International Pharmaceutical Regulation: Implications for the United States
39. Currie W. J. C. Löfgren M. (1996) Developments in International Pharmaceutical Regulation: Implications for the United States
40. www.eudra.org/emea.html [accessed February 1998].
41. Hennings G. (2000) ‘Marketing authorizations of medical products in the European Union: Past, present, and future’, Drug Information Journal, 34(3) pp. 793–2000.
42. McMahon E. (1995) New Drug Approval in Canada, Parexel, Inc.
43. Appel W. C. (1996) ‘Postmarketing surveillance in Canada’, Drug Information Journal, 30(3) pp. 655–659.
44. McMahon E. (1995) Drug Information Journal
45. McMahon E. (1995) Drug Information Journal
46. www.gov.on.ca/health/english/program/hed/reports/drugap1.html [accessed March 1999].